Costs of care with liver directed therapy (LDT) and sorafenib (S) in patients (pts) with hepatocellular carcinoma (HCC).

@article{Singavi2018CostsOC,
  title={Costs of care with liver directed therapy (LDT) and sorafenib (S) in patients (pts) with hepatocellular carcinoma (HCC).},
  author={Arun K Singavi and Aniko Szabo and James P. Thomas and Paul S. Ritch and Abdel Alqwasmi and Sarah B White and William S. Rilling and Ben George},
  journal={Journal of Clinical Oncology},
  year={2018},
  volume={36},
  pages={383-383}
}
383Background: 80% of HCC pts present with advanced disease, treatment for such pts is palliative in nature. It is important to ascertain cost associated with such palliative therapy, considering modest survival benefit afforded by these treatments. Methods: Utilizing a non-Medicare national claims database (MarketScan), we analyzed a cohort of pts with HCC diagnosis (Dx). Consistent with literature, pts selected had at least two claims with HCC code (155.0) between 1/1/2010 and 12/31/2013, at… 
2 Citations
Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review
TLDR
Better treatments are needed to extend survival and improve quality of life for patients with HCC.
Perceptions of Futility in Interventional Radiology: A Multipractice Systematic Qualitative Analysis
TLDR
This study characterized the complexity and qualitative nature of assessments of palliative verses futile care in IR while highlighting potential means of improving current practices given the number of critically ill patients referred to IR and costs of potentially inappropriate interventions.